Review · not a partner · checked August 2026
No 1-month price
We could not confirm what one month of treatment costs, with no commitment, from their public pages. Everything they do publish is below.
Every GLP-1 plan renews on a twelve-week subscription that Noom describes in months, so a year takes thirteen $179 payments and not twelve — and the same footnote appears twice on one page with two different starting prices.
Noom is the weight-loss app that added a clinic. The habit-change program is still the product it is famous for, and the GLP-1 programs bolt onto it: SmartDose titration, coaching, medication shipped to the door, or a telehealth-only path if you would rather use insurance for a brand drug.
The clinical side splits four ways — full-dose, microdose, a new prevention program, and prescriptions written for your own pharmacy — and each is priced differently. That is not the problem. The problem is the clock they are all billed on.
| Plan | Per month | Charged today |
|---|---|---|
| Microdose GLP-1 Rx, 12-week subscription · advertised | $179 | $537 |
Noom's own sentence, from its cost page on 2026-08-31: "Noom GLP-1Rx Program: A low-dose semaglutide plan starting at $79 for the first 4-week supply, then $537 every 12 weeks ($179 per month)." The multiplication holds — $179 x 3 is $537 — but a twelve-week subscription is not a quarter. Fifty-two weeks hold 4.33 of them, so a year is thirteen $179 payments, $2,327, rather than the twelve the phrase "per month" implies. The full-dose plan on the same page reads "Starts at $129 for the initial 4-week supply, then $279 per month" and states no renewal cycle at all; a table further down the page prices the full-dose tirzepatide program at "$149 initial 4-week supply, $299/month".
| Plan | Per month | Charged today |
|---|---|---|
| Microdose GLP-1 Rx Plus, 12-week subscription | $199 | $597 |
"Noom GLP-1Rx Plus Program: A low-dose tirzepatide plan starting at $99 for the first 4-week supply, then $597 every 12 weeks ($199 per month)." Same cadence, same arithmetic: $199 x 3 is $597 exactly, and 4.33 of those charges fill a 52-week year, which is thirteen $199 payments rather than twelve.
Noom prices in weeks and talks in months. The microdose semaglutide plan starts at $79 for the first four-week supply and then, in Noom's own words, costs "$537 every 12 weeks ($179 per month)." The multiplication is honest — $179 times three is $537 on the nose. The unit isn't. Twelve weeks is 84 days, and a 52-week year holds 4.33 of them, so you get billed $537 four and a third times. That is thirteen $179 payments a year, $2,327, against the $2,148 that "per month" gets a reader to.
The tirzepatide microdose runs the same way: $99 for the first four weeks, then $597 every 12 weeks, which Noom glosses as $199 a month. Thirteen of those is $2,587. And the very first period is odder still, because the footnote defining it reads "Initial 3 week subscription and 4 weeks of medication" — three weeks of subscription against four weeks of medicine, out of step before you have taken a dose.
The full-dose programs are quoted without a cycle at all: "Starts at $129 for the initial 4-week supply, then $279 per month" for semaglutide and $149 then $299 for tirzepatide. Noom's home page carries the same footnote grammar for a $349 plan — "$349 per month plus tax for 12 week subscription thereafter" — so on Noom's own pages a per-month figure is what a twelve-week subscription costs, divided by three.
Then there's the starting price, which depends on which sentence you land on. The home page banner says $49. The blog post's top footnote says $49. The same blog post's numbered footnote at the bottom says $79. The body and the summary table both say $79. Two versions of one footnote, one page, one day. The two footnotes even disagree about when the pricing took effect: one says "effective as of March 31, 2026" and the other "effective as of July 27, 2026."
The full breakdown — what is included, what is extra, and what happens at higher doses — is on the Noom cost page.
Anyone budgeting twelve payments. Noom bills on a twelve-week clock, so the year takes thirteen.
Anyone who wants a single month. There is no one-month rung here; the smallest unit Noom renews on is twelve weeks.
Anyone who read $49 on the banner. Noom's own cost page states the same offer at $79 four times and at $49 twice.
Anyone comparing Noom Med against an all-in price. The telehealth-for-brands path starts at $39 and explicitly excludes the medication.
| Prescriber licensed in your state | Not stated |
| Pharmacy named | Not named |
| What you get | Compounded semaglutide and tirzepatide with medication included; separately, telehealth for branded medications filled at a pharmacy of your choice, which Noom says is "Not available in all states" |
| Overseas fulfillment | Not stated |
| Support hours | Not published |
These are the checks this site applies to every company — how we review. Not stated means we could not find it on their site, which is a finding about the site, not about the company.
Prices read 2026-08-31 on noom.com. The microdose figures are verbatim from https://www.noom.com/blog/weight-management/noom-cost/: "Noom GLP-1Rx Program: A low-dose semaglutide plan starting at $79 for the first 4-week supply, then $537 every 12 weeks ($179 per month). Noom GLP-1Rx Plus Program: A low-dose tirzepatide plan starting at $99 for the first 4-week supply, then $597 every 12 weeks ($199 per month)."
The full-dose figures, same page, same day: "Noom GLP-1 Rx Program Starts at $129 for the initial 4-week supply, then $279 per month" and, from the comparison table below it, "Noom GLP-1 Rx Plus Program $149 initial 4-week supply -> $299/month" and "Telehealth for Branded Medications $39 (30-day trial)-> $129/month Not included (filled via your pharmacy of choice)". A fourth program is priced "$149 per month for a 4-month subscription, billed in monthly installments."
The duplicated footnote, both instances on https://www.noom.com/blog/weight-management/noom-cost/ read 2026-08-31. Near the top: "*Initial 3 week subscription and 4 weeks of medication from $49 plus tax and $179 per month plus tax for 12 week subscription thereafter. Final pricing depends on program selection." Numbered 1 at the bottom: "Initial 3-week subscription and 4 weeks of medication from $79 plus tax and $179 per month plus tax for a 12-week subscription thereafter. Final pricing depends on program selection." The first adds "New pricing for new accounts only effective as of July 27, 2026"; the home page's equivalent footnotes say "effective as of March 31, 2026".
The home page at https://www.noom.com/ carries two more variants of the same footnote on 2026-08-31: "1. Initial 3 week subscription and 4 weeks of medication from $149 plus tax and $349 per month plus tax for 12 week subscription thereafter" and "2. Initial 3 week subscription and 4 weeks of medication from $79 plus tax and $199 per month plus tax for 12 week subscription thereafter", above a banner reading "$49 Limited-Time Offer: Microdose GLP-1Rx Program (Compounded Semaglutide). Price includes medication."
The annual arithmetic, shown. Noom publishes $537 per twelve-week subscription. A 52-week year holds 52 divided by 12, which is 4.33 subscriptions, so the year costs 4.33 x $537 = $2,327. Noom's own gloss of $179 a month reaches $2,148 across twelve months. The difference, $179, is exactly one more of Noom's monthly figures — which is what happens when four-week medication cycles are described in calendar months.
What we could not find, and where we looked: we read https://www.noom.com/ and https://www.noom.com/blog/weight-management/noom-cost/ in full on 2026-08-31, searching each for licensed, state, 503A, 503B, pharmacy, overseas and hours. Neither states that the prescriber is licensed in the patient's own state, neither names a compounding pharmacy, neither addresses fulfillment outside the United States, and neither publishes support hours. Those four rows read Not stated on that basis. Noom does say the branded-medication path is "Not available in all states" and that compounded semaglutide sold through the program "is produced in an FDA-registered facility but has not been reviewed by the FDA for safety, efficacy, or quality."
Read on noom.com, not from a third party: the corporate line is "Copyright © 2026 Noom, Inc."
The same molecules at every other company we have reviewed, with the range each one falls in.
Noom's record is one of the inputs to these pieces, so a correction here moves their numbers too.
Words used above: Compounded, 503A, 503B, Overseas fulfillment. All of them are in the glossary.
Not a partner. This link goes to Noom and pays us nothing. Who pays us.
Every company we have reviewed is on the reviews index, and the reviews are written by Kevin Turner. Your privacy choices and the terms of use apply to this page.